News
SPONSORSHIPS
https://ce.dvm360.com/courses/blastomycosis-histoplasmosis-efficient-diagnosis-treatment-and-treatment-monitoring-1 https://ce.dvm360.com/courses/invasive-fungal-infections-not-invasive-diagnostic-investigations-fungal-biomarkers-in-cats-and-dogs https://ce.dvm360.com/courses/antifungal-therapy-in-small-animals-on-demand
Visit MiraVista Veterinary Diagnostics At VMX 2023 | Booth #5035
Representatives from MiraVista Veterinary Diagnostics will attend VMX 2023 in Orlando, Florida, from January 14th – January 18th. Visitors to our booth can register to win a BarkBox or meowbox giveaway. Our booth number is #5035. A map of the Orange County Conference Center Expo Hall in their South Concourse building can be found by...
Read More →
Read More →
MiraVista Partnered with DVM360 to Sponsor a 1-hr RACE® Approved Course
MiraVista partnered with DVM360 to sponsor a 1-hr RACE® approved course on antifungal therapy in small animals. Key Learning Objectives: Treatment of choice for common invasive fungal infections. Monitoring antifungal treatment to avoid adverse effects. Available options for salvage therapy. Click here to register for this complimentary, on-demand course.
VETgirl Podcast: Endemic Mycoses and Treatment
Dr. Hanzlicek presented a podcast on VETgirl, discussing endemic mycoses and treatment. Click the links below to listen to the presentation. On iTunes/Apple podcasts On our website
MiraVista – VetGirl
Dr. Andrew Hanzlicek presented a 1-hour webinar on VetGirl, discussing clinical review of antifungal treatment recommendations for common invasive fungal infections in dogs and cats, including blastomycosis, histoplasmosis, coccidioidomycosis, cryptococcosis, and opportunistic molds. View this webinar for free until April 24th, 2021 and learn more about what the future holds for antifungal therapies in veterinary...
Read More →
Read More →
Test Report Updates for 2021
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative EIA. The new test has high precision with 99% sensitivity and 100% specificity. Over 30 interfering substances were...
Read More →
Read More →
MiraVista to Receive Economic Incentives from IEDC for Expansion Efforts
Indiana Economic Development Corporation Offers $325,000 in economic incentives to MiraVista. This includes $275,000 in tax credits and $50,000 in training grants to hire additional employees and expand its corporate headquarters and diagnostic laboratory in Indianapolis.
Read More →
Read More →
CREDENTIALS:
